Aardvark Therapeutics Stock Surges 24% Premarket After FDA Lifts Clinical Hold on ARD-101

The Short Answer

Aardvark Therapeutics (Nasdaq: AARD) jumped about 24% in premarket trading on Friday, October 23, 2026, after the U.S. Food and Drug Administration lifted the clinical hold on ARD-101, its lead drug candidate for hyperphagia — excessive hunger — in Prader-Willi Syndrome (PWS). The hold had frozen the program since May. Aardvark announced the decision after the close on Thursday, October 22, and will review data from its terminated Phase 3 trials on a webcast at 8:00 a.m. ET today.

What Happened

Aardvark, a clinical-stage biopharmaceutical company based in San Diego, said on October 22 that the FDA lifted the clinical hold on its Investigational New Drug application for ARD-101. That means clinical development of the hunger-suppressing small-molecule drug for PWS may resume.

The stock had closed Thursday at $3.95, down 10.4% on the day, before the news landed. It rose about 14% to $4.52 in early after-hours trading, extended to roughly $4.98 (up about 26%), and was gapping up 24.3% in Friday premarket on about 811,000 shares — roughly six times its normal volume.

Why the Program Was Frozen

On February 27, 2026, Aardvark voluntarily paused dosing in its Phase 3 HERO trial and its open-label extension after reversible electrocardiogram (ECG) changes were spotted during routine safety monitoring in a separate study in healthy volunteers. In May 2026, the FDA placed a formal clinical hold on both trials.

Working in alignment with the FDA, the company then ran a thorough ECG study in additional healthy volunteers and an in vitro cardiac sodium channel (NaV1.5) study. The key result: no cardiac events were observed in the ECG study at ARD-101 doses of 200 mg and 400 mg twice daily. That clean heart-safety dataset is what cleared the way for the FDA to lift the hold.

Chief Executive Tien Lee said the company completed the work necessary to allow resumption of clinical studies, and noted that people living with PWS and their families continue to face profound unmet need.

Why It's Blowing Up

For a small clinical-stage biotech, a clinical hold on the lead program is often an existential event — and lifting one is the single biggest de-risking step short of trial success itself. ARD-101 is Aardvark's lead candidate, designed to suppress hunger by activating bitter taste receptors and gut signaling pathways. PWS is a rare genetic condition whose defining symptom is insatiable hunger, and treatment options remain extremely limited, which is why a regulatory green light here draws outsized attention relative to the company's size.

The timing adds fuel: Aardvark unblinded the data accumulated in the terminated HERO and open-label trials, and management will walk investors through that exploratory dataset on today's 8:00 a.m. ET webcast — right in the middle of the premarket session, so the stock could move again in either direction on what that data shows.

Key Facts

• Company: Aardvark Therapeutics, Inc. (Nasdaq: AARD), San Diego, California
• News: FDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi Syndrome (announced October 22, 2026, 4:05 p.m. ET)
• Stock reaction: Closed $3.95 (-10.4%) Thursday; up ~26% after hours to ~$4.98; +24.3% premarket Friday on ~6x normal volume
• Hold history: Dosing paused February 27, 2026 over reversible ECG changes; FDA clinical hold imposed May 2026
• What cleared it: New ECG study showed no cardiac events at 200 mg and 400 mg twice daily, plus an in vitro NaV1.5 study
• Next event: Webcast Friday, October 23, 2026 at 8:00 a.m. ET reviewing terminated Phase 3 HERO / open-label data

What's Next

A lifted hold is permission to resume — not a restarted trial and not an approval. Aardvark says it plans to resume clinical development in PWS patients after further engagement and alignment with the FDA on the Phase 3 trial design, and it has not given a restart timeline. The company remains clinical-stage and unprofitable, and the stock had fallen sharply over the past year before this rebound, so volatility is likely to stay high around the webcast and any Phase 3 design update. This post reports what happened and why markets reacted; it is not financial advice.

Sources

• Aardvark Therapeutics / GlobeNewswire — FDA lifts clinical hold on ARD-101
• Morningstar / Dow Jones Newswires — FDA lifts Aardvark clinical hold, shares rise
• StockMarketWatch — October 23 premarket movers: AARD +24.3%
• Tech and Money Press — Stocks to watch Friday, Oct. 23: Aardvark

FAQ

Why did Aardvark Therapeutics stock jump today?

AARD rose about 24% premarket on October 23, 2026 because the FDA lifted the clinical hold on ARD-101, allowing development of its lead Prader-Willi Syndrome drug to resume.

What is ARD-101?

ARD-101 is Aardvark's lead small-molecule drug candidate designed to suppress hunger, being developed for hyperphagia (excessive hunger) in Prader-Willi Syndrome.

Why was ARD-101 on clinical hold?

Dosing was paused in February 2026 after reversible ECG changes appeared in a healthy-volunteer study, and the FDA imposed a formal hold in May 2026; a follow-up ECG study showed no cardiac events at 200 mg and 400 mg twice daily.

What happens next for Aardvark?

The company reviews its terminated Phase 3 HERO trial data on an October 23, 8:00 a.m. ET webcast, then must align with the FDA on a new Phase 3 design before restarting trials — no timeline has been given.